Cardiac STATus®

The Cardiac STATus brand of rapid cardiac marker tests has been a standard of care delivering trusted results for more than ten years in hospitals, emergency rooms, and other urgent care settings.  Cardiac STATus is intended for use as an aid in the diagnosis of myocardial infarction (MI).

"This year about 1.2 million Americans will have a first or recurrent coronary attack.  About 452,000 of these people will die.  Coronary heart disease is the nation's single leading cause of death." ¹

Nanogen offers Cardiac STATus in two configuration: as a stand alone Troponin I test and as a 3-in-1 Troponin I, Myoglobin, and CK-MB test.  Stemming from the need to test multiple biomarkers for myocardial damage at once, Nanogen developed the Troponin, Myoglobin, and CK-MB combination test and its' patented 3-in-1 design.  Companies can license Nanogen's 3-in-1 design for use in their products.  All Cardiac STATus products are FDA 510 cleared.

The failure to hospitalize patients with acute myocardial infarction or unstable angina who present to the emergency department is a serious public health issue. Studies have found that between 2 percent and 8 percent of patients with acute myocardial infarction who present to the emergency department are sent home.²  With results in 15 minutes, Cardiac STATus uses diagnostic technology that allows the flexibility and ease of use that is demanded in emergency situations. 

"The laboratory should perform cardiac marker testing with a turnaround time of 1 hour, optimally 30 minutes or less." ¹

In the midst of a typically chaotic environment, Cardiac STATus enables healthcare professionals to quickly assess cardiac biomarker status for patients experiencing chest pain.  Not only is this better patient care, but it is more cost-efficient.

Flexible Technology

• Qualitative results with reliable cardiac markers (Troponin I, Myoglobin, and/or CK-MB)
• Stored at room temperature
• Transfer pipette included.  No decapping necessary.
• FDA 510 cleared

Rapid, Reliable Results

• Lab-correlated results in 15 minutes
• Meets the American College of Cardiology (ACC), American Heart Association (AHA), and European Society of Cardiology (ESC) guidelines
• Utilizes the renowned 8-17 antibody in a sandwich assay for superior Troponin I capture and avoids interfering factors
• Captures both ST-elevated myocardial infarction (STEMI) and non ST-elevated myocardial infarction (non-STEMI) conditions

Easy to Use

• 1-step process
• Simple to read

 

¹  Know the Facts, Get the Stats 2007.  American Heart Association | American Stroke Association Learn and Live.  2007.

²  Pope, MD, J. Hector, et al.  Missed Diagnosis of Acute Cardiac Ischemia in the Emergency Department.  New England Journal of Medicine.  April 20, 2000; 342:1163-70.